增强嵌合抗原受体T细胞功能在复发难治B细胞恶性肿瘤治疗中的研究进展  

Progress of enhancing the function of chimeric antigen receptor T-cells in replased/refractory B-cell malignancies

作　　者：赵国兴 程志 韦润红 Zhao Guoxing;Cheng Zhi;Wei Runhong(Department of Hematology,Henan Province Hospital of Traditional Chinese Medicine(the Second Affiliated Hospital of Henan University of Traditional Chinese Medicine),Institute of Hematology,Henan University of Traditional Chinese Medicine,Zhengzhou 450002,China)

机构地区：[1]河南省中医院(河南中医药大学第二附属医院)血液科河南中医药大学血液病研究所,郑州450002

出　　处：《白血病．淋巴瘤》2021年第8期508-512,共5页Journal of Leukemia & Lymphoma

摘　　要：嵌合抗原受体T细胞(CAR-T)治疗复发难治B细胞恶性肿瘤无效时,尝试增强CAR-T功能来提高疗效,是药物研发和临床研究的一个新热点。近年来,这方面已经取得显著成绩。多靶点CAR-T、来那度胺、地西他滨、程序性死亡受体1抑制剂以及伊布替尼等均能增强CAR-T功能。文章对近年来在复发难治B细胞恶性肿瘤治疗中增强CAR-T功能的研究进展进行综述。When chimeric antigen receptor T cells(CAR-T)failed to treat relapsed and refractory B-cell malignancies,some researchers try to improve the efficacy by enhancing the function of CAR-T.It is a new hotspot of drug development and clinical research,and significant achievements have been made in this area recently.Multi-targeted CAR-T,lenalidomide,decitabine,programmed death 1 inhibitor and ibrutinib can all enhance the function of CAR-T.This article reviews the recent progress of enhancing the function of CAR-T in relapsed and refractory B-cell malignancies.

关 键 词：嵌合抗原受体T细胞 B细胞恶性肿瘤 复发 难治 来那度胺 地西他滨 伊布替尼 程序性死亡受体1抑制剂 

分 类 号：R733.1[医药卫生—肿瘤]